About Enoyl-CoA hydratase domain-containing protein 2, mitochondrial
Enoyl-CoA hydratase domain-containing protein 2, mitochondrial (ECHDC2) is a protein
from Homo sapiens identified by UniProt accession
Q86YB7, 292 residues long.
MolForge cross-references it against 0 known binders and
36 disease associations.
Target properties
| Protein name | Enoyl-CoA hydratase domain-containing protein 2, mitochondrial |
|---|
| UniProt accession | Q86YB7 |
|---|
| Gene | ECHDC2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 292 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (36)
Diseases linked to this target (Open Targets).
- red blood cell density measurement · score 0.16
- hemoglobin measurement · score 0.12
- monocyte count · score 0.11
- erythrocyte count · score 0.11
- hemoglobin A1 measurement · score 0.10
- thyroid disease · score 0.09
- monocyte percentage of leukocytes · score 0.09
- mean reticulocyte volume · score 0.09
- mean corpuscular hemoglobin concentration · score 0.08
- hematocrit · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86YB7-F1 | alphafold | PREDICTED | 92.38 | — |
Amino-acid sequence (292 residues)
MLRVLCLLRP WRPLRARGCA SDGAAGGSEI QVRALAGPDQ GITEILMNRP SARNALGNVF VSELLETLAQ LREDRQVRVL LFRSGVKGVF CAGADLKERE QMSEAEVGVF VQRLRGLMND IAAFPAPTIA AMDGFALGGG LELALACDLR VAASSAVMGL IETTRGLLPG AGGTQRLPRC LGVALAKELI FTGRRLSGTE AHVLGLVNHA VAQNEEGDAA YQRARALAQE ILPQAPIAVR LGKVAIDRGT EVDIASGMAI EGMCYAQNIP TRDRLEGMAA FREKRTPKFV GK
Explore Enoyl-CoA hydratase domain-containing protein 2, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets